NCT02606305
|
Phase I |
Bevacizumab
Carboplatin
Doxorubicin
Mirvetuximab Soravtansine
|
Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer |
Recruiting |
NCT01609556
|
Phase I |
Mirvetuximab Soravtansine
|
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors |
Active, not recruiting |
NCT03106077
|
Phase II |
Mirvetuximab Soravtansine
|
Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) |
Recruiting |
NCT03832361
|
Phase II |
Mirvetuximab Soravtansine
|
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer |
Not yet recruiting |
NCT02631876
|
Phase II |
Doxil + Paclitaxel
Gemcitabine
Topotecan
Mirvetuximab Soravtansine
|
PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer |
Active, not recruiting |
NCT02996825
|
Phase I |
Mirvetuximab Soravtansine
|
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer |
Recruiting |